Endothelial progenitor cells (EPC) are good candidates for cell-based therapy in cardiovascular diseases. However, concerns have been raised about the potential risks of EPC-based cell therapy, in terms of thrombogenicity particularly in inflammatory conditions, currently observed in such patients. Tissue factor (TF) can trigger coagulation and may support thrombogenicity. TF is also a key receptor in angiogenesis.
Tissue factor up-regulation in proinflammatory conditions confers thrombin generation capacity to endothelial colony-forming cells without influencing non-coagulant properties in vitro.
Laboratoire d'Hématologie, CHU Robert Debré and EA-3801, Faculté de Médecine, IFR-53 Interactions Cellules MicroEnvironnement, Université de Reims Champagne-Ardenne, Reims, France.
